Dual targeting of MYC and CYCLON by BET bromodomain inhibition optimizes Rituximab response in lymphoma.

ChEBI2013-06-01 更新2026-07-21 收录

淋巴瘤靶向治疗

BET抑制剂

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-46873 数据链接链接失效反馈

官方服务：

资源简介：

Dual targeting of MYC and CYCLON by BET bromodomain inhibition optimizes Rituximab response in lymphoma.

创建时间：

2013-06-01

BRD4 loading at the transcription start site mediates pause-release and underlies the disproportionate transcriptional response to BET bromodomain inhibition [RNA-Seq]

转录暂停释放调控

BET抑制剂

BET bromodomain inhibition (BETi) abrogates cancer cell growth by disrupting oncogenic gene expression. BRD4 loading at enhancers has been suggested to mediate pause-release and underlie the selective

NIAID Data Ecosystem100

Mechanistic basis and efficacy of targeting Beta Catenin-TCF7L2-JMJD6-MYC Axis to overcome resistance to BET inhibitors [no drug]

BET抑制剂

急性髓系白血病(AML)研究

Promising activity of BET protein inhibitors (BETis) is compromised by adaptive or innate resistance in AML. Here, modeling of BETi- persister/resistance (BETi-P/R) in human post-MPN secondary AML (s

NIAID Data Ecosystem80

Table_1_The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.XLSX

淋巴瘤靶向治疗

多药耐药逆转

The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 t

NIAID Data Ecosystem50

Physachenolide C is a Potent, Selective BET Inhibitor

BET抑制剂

前列腺癌靶向治疗

A pulldown using a biotinylated natural product of interest in the 17β-hydroxywithanolide (17-BHW) class, physachenolide C (PCC), identified the bromodomain and extra-terminal domain (BET) family of p

Figshare2022-12-28 更新80

Triple combination of BET plus pan-PI3K and NF-?B inhibitors exhibit synergistic activity in adult T cell leukemia/lymphoma

淋巴瘤靶向治疗

天然药物组合

We exploited the use of I-BET762, copanlisib, and bardoxolone methyl inhibitors as triple combination to understand the interactions between these three pathways in Adult T cell leukemia/lymphoma. Ove

NIAID Data Ecosystem50

Dual targeting of MYC and CYCLON by BET bromodomain inhibition optimizes Rituximab response in lymphoma.

资源简介：

相关数据集